Treatment | Page 321 of 465

Purpura :: Eltrombopag decreased bleeding episodes and improved platelet counts in idiopathic thrombocytopenic purpura

GlaxoSmithKline (GSK) today announced additional results from an international Phase II short-term, six-week study of its investigational non-peptide oral platelet growth factor, eltrombopag. Analysis of data from this study showed that eltrombopag at 50mg or 75mg, resulted in a positive trend in decrease in bleeding incidence (all grades) in adult patients with chronic idiopathic thrombocytopenic purpura (ITP), an autoimmune condition which results in low blood platelet counts and bleeding from the small blood vessels. These data were presented today at the 48th Annual American Society of Hematology (ASH) meeting in Orlando, Florida.

Leukemia :: Campath Superior to Chlorambucil in leukemia

Genzyme Corporation (Nasdaq: GENZ) and Berlex Inc., a U.S. affiliate of Schering AG, Germany (FSE: SCH), majority-owned by the Bayer Group, today announced results from CAM307, an international Phase III clinical trial comparing Campath(R) (alemtuzumab) with chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukemia (B-CLL).

Ears :: Antibiotic ear drops favored over popular oral antibiotics for ear infections

A multicenter study on treating common ear infections in children with ear tubes adds to a growing body of evidence that favors antibiotic ear drops over antibiotics swallowed in pill or liquid form in such cases, a UT Southwestern Medical Center researcher reports.

Nystagmus :: Leicester breakthrough in eye disease

Researchers at the University of Leicester have identified for the first time a gene which causes a distressing eye condition. Their discovery, as reported in the journal Nature Genetics, is expected to lead to better treatments for the condition.

Malaria :: Stop marketing unapproved drug products containing quinine – FDA

The Food and Drug Administration (FDA) today ordered firms to stop marketing unapproved drug products containing quinine, a drug used to treat malaria, citing serious safety concerns, including deaths, associated with quinine products. There are multiple unapproved products containing quinine currently marketed. However, there is only one quinine product approved by the FDA.

Prostate Cancer :: older men with early prostate cancer treated lived longer

SEER-Medicare analysis finds older men with early prostate cancer who were treated lived longer than those who were not treated. Study published in Dec. 13th issue of JAMA.

Folic Acid :: Folic acid won’t cut heart, stroke risk

An analysis of previous studies suggests that for people with a history of vascular disease, folic acid supplementation does not decrease the risk of coronary heart disease or stroke, as has been suggested in some research, according to a review article in the December 13 issue of JAMA.

Anthrax :: Microneedle Vaccination Technique Protects Rabbits Against Inhalation Anthrax Using Smaller Dosage

Microneedle-based vaccination with the current anthrax vaccine produced an equally effective immune response to intramuscular injection in rabbits using smaller dosage say researcher from Maryland and North Carolina. They report their findings in the December 2006 issue of the journal Infection and Immunity.

Influenza :: Novel Peptide Targets Viral Cells and May Inhibit Influenza Virus Infection

Researchers from the University of Wisconsin have identified a novel antiviral peptide that may inhibit influenza viruses including the H5N1 strain. They report their findings in the December 2006 issue of the Journal of Virology.

Prostate Cancer :: Older men treated for early prostate cancer live longer than those who are not

Recent findings of an observational study by researchers at the University of Pennsylvania School of Medicine suggest that men between 65-80 years of age who received treatment for early stage, localized prostate cancer lived significantly longer than men who did not receive treatment. The study will be published in the Dec. 13 issue of JAMA.